asked the Secretary of State for Social Services why he announced proposals for major changes in the system of giving approval to pharmaceutical firms wishing to launch clinical trials of new compounds at the dinner of the pharmaceutical industry rather than to Parliament; what are the basic elements of the changes; and if he will make a statement.
I refer the right hon. Gentleman to my reply to my hon. Friend the Member for Surrey, Northwest (Mr. Grylls), on 17 April.—[Vol. 982, c. 695–6].